References
- Kamal R, McDermott D, Cox C. How has U.S. spending on healthcare changed over time? Peterson-KFF (Kaiser) Health System Tracker. 2019 [accessed 2020 Apr 7]. Available from: https://www.healthsystemtracker.org/chart-collection/u-s-spending-healthcare-changed-time/#item-start
- Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018; 319(10):1024–1039.
- Peter G. Peterson Foundation. How does the US healthcare system compare to other countries? [accessed 2020 Apr 9]. Available from: https://www.pgpf.org/blog/2019/07/how-does-the-us-healthcare-system-compare-to-other-countries
- Pavoola A. US drug spending to top $370B this year, Fitch Solutions says. Becker’s Hospital Review. 2019 May 28 [accessed 2020 Apr 27]. Available from: https://www.beckershospitalreview.com/pharmacy/us-drug-spending-to-top-370b-this-year-fitch-solutions-says.html
- Public Law115–97. An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018. 2017 Dec 22.
- Dieleman JL, Squires E, Bui AL, et al. Factors associated with increases in US health care spending, 1996–2013. JAMA. 2017;318(17):1668–1678.
- Emanuel EJ. Big pharma’s go-to defense of soaring drug prices doesn’t add up. The Atlantic. 2019 Mar 23 [accessed 2020 Apr 19]. Available from: https://www.theatlantic.com/health/archive/2019/03/drug-prices-high-cost-research-and-development/585253/
- Mendoza RL. Incentives and disincentives to drug innovation: evidence from recent literature. J Med Econ. 2019;22(8):713–721.
- 2020 Annual Meeting of the American Economics Association in Conjunction with the Allied Social Sciences Association (AEA-ASSA); 2020 Jan 2–6; San Diego, CA.
- Culyer AJ. A Glossary of the more common terms encountered in health economics. In: Hersh-Cochran MS, Cochran KP, editors. Compendium of English language course syllabi and textbooks in health economics. Copenhagen: World Health Organization; 1989. p. 215–234.
- Wang LX. Global drug diffusion and innovation with a patent pool: the case of HIV drug cocktails. Paper presented at: the 2020 annual meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 3; San Diego, CA.
- Lemus J, Ozkul O. Product hopping and innovation incentives. Paper presented at the 2020 annual meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 4; San Diego, CA.
- Feng J, Hwang T, Maini L. The ACA Medicaid rebate rule change: impact on pricing and innovation. Paper presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 5; San Diego, CA.
- Bonaime A, Wang Y. Mergers, product prices, and innovation: evidence from the pharmaceutical industry. Paper presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 3; San Diego, CA.
- Krieger J, Higgins M, Li D, et al. Paving the way: follow-on innovation and spillovers in drug development. Paper presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 5; San Diego, CA.
- Kaplan C, Hayes T. Price sensitivity and substitution among prescription medications: evidence from the Medicare Part D donut hole closure. Poster session presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 3–5; San Diego, CA.
- Kaliski D. Does insurance for treatment crowd out prevention? Evidence from diabetics’ insulin usage. Paper presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 4; San Diego, CA.
- DiNardi M. Uninsurance and purchases of addictive prescription drugs: evidence from the Federal Dependent Coverage Mandate. Poster session presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 3–5; San Diego, CA.
- Goldin J, Lurie IZ, McCubbin J. Health insurance and mortality: experimental evidence from taxpayer outreach. Paper presented at: the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 4; San Diego, CA.
- Deaton A. Journal of Econometrics panel: econometrics in the 21st century, challenges and opportunities. Lecture delivered at the 2020 Annual Meeting of the American Economics Association and Allied Social Sciences Association (AEA-ASSA); 2020 Jan 4; San Diego, CA.
- Gatwood J, Gibson TB, Chernew ME, et al. Price elasticity and medication use: cost sharing across multiple clinical conditions. J Manag Care Spec Pharm. 2014;20(11):1102–1107.
- Tribble SJ. Why the U.S. remains the world’s most expensive market for ‘biologic’ drugs. Kaiser Health News. 2018 Dec 20 [accessed 2020 May 8]. Available from: https://khn.org/news/u-s-market-forbiologic-drugs-is-most-expensive-in-the-world/
- Mendoza RL. Bringing the patient back in: behavioral decision-making and choice in medical economics. J Med Econ. 2018; 21(4):313–317.
- Kissick WL. Medicine’s dilemmas: infinite needs versus finite resources. New Haven (CT): Yale University Press; 1994.
- Siwicki B. Here are 6 major issues facing healthcare in 2019, according to PwC. Healthcare IT News. 2019 Jan 17 [accessed 2020 May 19]. Available at: https://www.healthcareitnews.com/news/here-are-6-major-issues-facing-healthcare-2019-according-pwc